Dr. rer. nat Karsten Bamminger, MScPostdoctoral researcher
Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Research Associate (Postdoc)
ORCID: 0000-0003-3811-7485
karsten.bamminger@meduniwien.ac.at
Keywords
Biomarkers, Pharmacological; Positron-Emission Tomography; Programmed Cell Death 1 Receptor
Research group(s)
- Radiochemistry and Biomarker Development
Members: - Experimental Nuclear Medicine
Head: Cécile Philippe
Research Area: The research group "Experimental Nuclear Medicine" deals with the development and evaluation of radiotracers in various diseases. In addition, the group focuses on organ axes and pharmacokinetics.
Members:
Research interests
My research focuses primarily on the development of PET tracers for the diagnosis and treatment of cancers and other malignancies. The ultimate goal is to achieve a better patient stratification to improve therapy response and survival.
Selected publications
- Bamminger, K. et al. (2024) ‘Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1’, Journal of Medicinal Chemistry, 67(5), pp. 4036–4062. Available at: https://doi.org/10.1021/acs.jmedchem.3c02342.
- Bamminger, K. et al. (2023) ‘On the Road towards Small-Molecule Programmed Cell Death 1 Ligand 1 Positron Emission Tomography Tracers: A Ligand-Based Drug Design Approach’, Pharmaceuticals, 16(7), p. 1051. Available at: https://doi.org/10.3390/ph16071051.
- Bamminger, K. et al. (2022) ‘Rapid, high-yield enzymatic synthesis of n.c.a. 6-[18F]fluorodopamine (6-[18F]FDA) for in vivo application’, Nuclear Medicine and Biology, 114–115, pp. 189–197. Available at: https://doi.org/10.1016/j.nucmedbio.2022.07.001.
- Bauer, M. et al., 2021. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 23(2), pp.180–185. Available at: http://dx.doi.org/10.1007/s11307-021-01582-4.
- Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics, 109(3), pp.754–761. Available at: http://dx.doi.org/10.1002/cpt.2052.